Correlation between intravesical prostatic protrusion and prostate volume in patients presenting with acute urinary retention: A descriptive study by Jishnu, Palliyani
  
“CORR
PROT
PRESE
THE TA
SREE
ELATION
RUSION 
NTING 
MIL NADU
In 
DR. JAY
DEPA
 MOOKA
KU
 BETWE
AND PRO
WITH AC
DESCR
DR. JIS
Disserta
 DR. M.G
partial fulfi
fo
M S GEN
Unde
AKUMAR
P
RTMENT
MBIKA IN
LASEKAR
A
 
EN INTR
STATE V
UTE UR
IPTIVE S
BY 
HNU PALL
tion submitt
.R. MEDIC
 
 
 
 
llment of the
r the degree 
ERAL SU
BRANCH I
r the guidan
 SAHAYAM
ROFESSO
 OF GENE
STITUTE 
AM, KAN
 
PRIL 2018
AVESIC
OLUME
INARY R
TUDY” 
IYANI 
ed to the 
AL UNIVE
 requiremen
of 
RGERY 
 
ce of 
 M S (Gener
R  
RAL SURG
OF MEDIC
YAKUMA
 
AL PROS
 IN PATI
ETENTI
RSITY, CH
ts 
al Surgery) 
ERY 
AL SCIEN
RI 
TATIC 
ENTS 
ON- A 
ENNAI 
CES 
 SREE MOOKAMBIKA INSTITUTE OF MEDICAL 
SCIENCES, 
KULASEKARAM 
 
DECLARATION BY THE CANDIDATE 
 
 I hereby declare that this dissertation entitled “CORRELATION 
BETWEEN INTRAVESICAL PROSTATIC PROTRUSION AND 
PROSTATE VOLUME IN PATIENTS PRESENTING WITH ACUTE 
URINARY RETENTION- A DESCRIPTIVE STUDY” is a bonafide and 
genuine research work carried out by me under the guidance of Dr. 
Jayakumar Sahayam MS (General Surgery), Professor, Department of 
General Surgery, Sree Mookambika Institute Of Medical Sciences, 
Kulasekaram. 
 
 
 
Date:             Dr.Jishnu Palliyani 
Place: Kulasekaram     Post Graduate 
       Dept. Of General Surgery 
       Sree Mookambika Institute Of 
Medical 
Sciences, Kulasekaram 
 
 SREE MOOKAMBIKA INSTITUTE OF MEDICAL 
SCIENCES, 
KULASEKARAM 
 
CERTIFICATE BY THE GUIDE  
 
 This is to certify that the dissertation “CORRELATION BETWEEN 
INTRAVESICAL PROSTATIC PROTRUSION AND PROSTATE 
VOLUME IN PATIENTS PRESENTING WITH ACUTE URINARY 
RETENTION- A DESCRIPTIVE STUDY” is a bonafide and genuine 
research work carried out by Dr. Jishnu Palliyani  under my guidance, in 
partial fulfillment of the requirement for the degree of M S in General 
Surgery. 
 
 
 
Date:       Dr. Jayakumar Sahayam.  
MS 
Place: Kulasekaram     (General Surgery) 
       Professor  
       Dept. Of General Surgery 
           Sree Mookambika Institute Of 
Medical Sciences, Kulasekaram  
  
 SREE MOOKAMBIKA INSTITUTE OF MEDICAL 
SCIENCES, 
KULASEKARAM 
 
CERTIFICATE BY THE GUIDE  
 
 This is to certify that the dissertation “CORRELATION BETWEEN 
INTRAVESICAL PROSTATIC PROTRUSION AND PROSTATE 
VOLUME IN PATIENTS PRESENTING WITH ACUTE URINARY 
RETENTION- A DESCRIPTIVE STUDY” is a bonafide and genuine 
research work carried out by Dr. Jishnu Palliyani  under my guidance, in 
partial fulfillment of the requirement for the degree of M S in General 
Surgery. 
 
 
 
Date:       Dr. Satish Babu 
Place: Kulasekaram     Associate Professor   
         Dept. Of 
Radiodiagnosis 
           Sree Mookambika Institute Of 
Medical Sciences, Kulasekaram  
  
 SREE MOOKAMBIKA INSTITUTE OF MEDICAL 
SCIENCES, 
KULASEKARAM 
 
CERTIFICATE BY THE HEAD OF DEPARTMENT 
 
 I hereby declare that this dissertation entitled “CORRELATION 
BETWEEN INTRAVESICAL PROSTATIC PROTRUSION AND 
PROSTATE VOLUME IN PATIENTS PRESENTING WITH ACUTE 
URINARY RETENTION- A DESCRIPTIVE STUDY” is a bonafide and 
genuine research work carried out by Dr. Jishnu Palliyani, under my overall 
supervision in the Department of General Surgery, Sree Mookambika Institute 
Of Medical Sciences, Kulasekaram. 
 
 
 
Date:       Dr. Soundara Rajan MS 
Place: Kulasekaram     (General Surgery) 
       Professor & HOD 
       Dept. Of General Surgery 
           Sree Mookambika Institute Of 
Medical Sciences, Kulasekaram 
 
 
 SREE MOOKAMBIKA INSTITUTE OF MEDICAL 
SCIENCES, 
KULASEKARAM 
 
 
ENDORSMENT BY THE DIRECTOR 
 
 This is to certify that the dissertation entitled “CORRELATION 
BETWEEN INTRAVESICAL PROSTATIC PROTRUSION AND 
PROSTATE VOLUMEIN PATIENTS PRESENTING WITH ACUTE 
URINARY RETENTION- A DESCRIPTIVE STUDY” is a bonafide and 
genuine research work carried out by Dr.Jishnu Palliyani under the guidance 
of Dr. Jayakumar Sahayam. MS (General Surgery), Professor, Department of 
General Surgery, Sree Mookambika Institute Of Medical Sciences, 
Kulasekaram. 
 
 
 
Date:       DR. REMA. V. NAIR, MD, 
DGO 
Place: Kulasekaram 
       DIRECTOR 
       SREE MOOKAMBIKA 
INSTITUTE 
OF MEDICAL SCIENCES, 
       KULASEKARAM 
 
 
  
COPYRIGHT 
 
 
DECLARATION BY THE CANDIDATE 
 
 
 I hereby declare that The Tamil Nadu Dr. M.G.R. Medical University, 
Chennai shall have the rights to preserve, use and disseminate this dissertation 
in print or electronic format for academic/research purpose. 
 
 
 
 
 
 
Date:              Dr.Jishnu Palliyani 
Place: Kulasekaram      Post Graduate 
        Dept. Of General 
Surgery 
        Sree Mookambika 
Institute 
of Medical Sciences, Kulasekaram 
 
 
 
 
© The Tamil Nadu Dr. M.G.R. Medical University, Madras 
 
 ACKNOWLEDGEMENT 
First and foremost, my salutations to GOD THE ALMIGHTY for his divine 
grace bestowed when needed. With proud privilege and deep sense of respect, I 
express my gratitude and indebtedness to my teacher and guide 
DR.JAYAKUMAR SAHAYAM. MS(General Surgery), Professor, 
Department  Of General Surgery, Sree Mookambika Institute Of Medical 
Sciences, Kulasekaram., for his constant inspiration, patience, encouragement 
and support, which rendered in preparing this dissertation and in pursuit of my 
post graduate studies.  
I express my gratitude to DR. SATISH BABU, Associate Professor, 
Department of Radiodiagnosis, Sree Mookambika Institute Of Medical 
Sciences, Kulasekaram, for his guidance and support throughout the course of 
this dissertation.  
It is with immense gratitude that I acknowledge  the support and guidance of 
our Head  of  the Department, DR. SOUNDARA RAJAN, for his dedication 
and for being a constant source of inspiration through out the course of this 
dissertation. 
I am forever grateful to my Professors, Dr.Pratap Gnanamuttu, 
Dr.D.Balajee, Madhumohan, Dr. Maheswari; Associate Professors, 
Dr.U.Arunchalam, and also Assistant Professors, Dr.C.Ponmudi, 
Dr.Chandrasekar, Dr.Arun K.Gowda, and Dr.Subash Naraintran for their 
valuable help, and guidance when required during my study. 
 I am grateful to Dr. C.K.Velayuthan Nair and Dr. Rema.V.Nair, our 
Chairman and Director respectively, Sree Mookambika Institute Of Medical 
Sciences, Kulasekaram, for permitting me to utilize hospital resourses during 
my study period.  
I am thankful to my colleagues Dr. Firas  Mohammed Anwar Mathery, Dr. 
Vishnu R Krishnan, my juniors Dr. Deepam Das, Dr. Karthika 
Sanalkumar and  Dr. Soumya Shree Singhal and my dear interns for their 
cooperation. 
I express my thanks to one and all in the department of General Surgery, 
medical records section, library staff and all hospital staff for their kind 
cooperation in my study. I convey my heartfelt gratitude to all my patients 
without whose cooperation this study would have been incomplete. 
No amount of words can measure my deep sense of gratitude and fullness that I 
feel towards my parents Mr. Palliyani Muraleedharan. and Mrs. Geetha 
Muraleedharan along with my sister Mr. Praseeda Muraleedharan whose 
cherished blessings and constant persuasion has made me reach this stage. I 
owe my support to my family for their countless sacrifices, love, 
encouragement, and support. 
 
Date: 
Place: Kulasekaram    DR. JISHNU PALLIYANI 
 
  
  
 LIST OF TABLES 
Sl.No
. TABLE 
Pg.No
. 
1. INTERNATIONAL PROSTATE SYMPTOM SCORE 24 
2. QUALITY OF LIFE SCORE 26 
3. GRADING OF PROSTATE BY DRE 27 
4. DISTRIBUTION ACCORDING TO AGE 51 
5. AGE DISTRIBUTION IN STUDY POPULATION 52 
6. DISTRIBUTION OF PROSTATE VOLUME 53 
7. DISTRIBUTION OF IPP 54 
8 
PREVALENCE OF SIGNIFICANT IPP IN STUDY 
POPULATION  
55 
9. DISTRIBUTION OF PROSTATE GRADE 56 
10. 
DISTRIBUTION OF PROSTATE GRADE AMONG 
PATIENTS WITH SIGNIFICANT IPP 
58 
11. 
DISTRIBUTION OF IPP IN DIFFERENT AGE 
GROUPS 
58 
12. DISTRIBUTION OF INCOMPLETE EMPTYING 59 
13. DISTRIBUTION OF INCREASED FREQUENCY 61 
14. 
DISTRIBUTION OF INTERMITTENCY WHILE 
VOIDING 
62 
 15. DISTRIBUTION OF URGENCY OF MICTURITION 63 
16. DISTRIBUTION OF WEAK STREAM 64 
17. DISTRIBUTION OF STRAINING WHILE VOIDING 65 
18. DISTRIBUTION OF NOCTURIA 66 
19. DISTRIBUTION OF QUALITY LIFE SCORING 67 
20. DISTRIBUTION OF IPSS 68 
21. DISTRIBUTION OF IPSS GRADES 69 
22. DISTRIBUTION OF PREVIOUS AUR 70 
23. 
DISTRIBUTION OF PUS CELLS IN URINE 
EXAMINATION 
71 
24. DISTRIBUTION OF PROSTATE TENDERNESS 72 
25. 
CORRELATION BETWEEN INTRAVESICAL 
PROSTATIC PROTRUSION AND PROSTATE 
VOLUME 
73 
 
 
 
 
 
 LIST OF GRAPHS 
Sl.No
. 
GRAPH Pg.No. 
1. AGE DISTRIBUTION IN STUDY POPULATION 52 
2. PREVALENCE OF SIGNIFICANT IPP 55 
3. DISTRIBUTION OF PROSTATE GRADE 57 
4. DISTRIBUTION OF INCOMPLETE EMPTYING 60 
5. DISTRIBUTION OF INCREASED FREQUENCY 61 
6. DISTRIBUTION OF INTERMITTENCY WHILE 
VOIDING 
62 
7. DISTRIBUTION OF URGENCY OF MICTURITION 63 
8. DISTRIBUTION OF WEAK STREAM 64 
9. DISTRIBUTION OF STRAINING WHILE VOIDING 65 
10. DISTRIBUTION OF NOCTURIA 66 
11. DISTRIBUTION OF QUALITY LIFE SCORING 67 
12. DISTRIBUTION OF IPSS GRADES 69 
13. DISTRIBUTION OF PREVIOUS AUR 70 
14. DISTRIBUTION OF PUS IN URINE EXAMINATION 71 
15. DISTRIBUTION OF PROSTATE TENDERNESS 72 
 
 
 LIST OF FIGURES 
Sl.No. FIGURE Pg.No. 
1. PROSTATE GLAND AND PROSTATIC 
URETHRA 
6 
2. ZONES OF PROSTATE 11 
3. ZONAL ANATOMY OF THE PROSTATE 12 
4. PROSTATE AND THE PROSTATIC URETHRA 14 
5. SURGICAL ANATOMY OF PROSTATECTOMY 14 
6. ARTERIAL SUPPLY OF PROSTATE 15 
7. PROSTATE VOLUME MEASUREMENT 30 
8. MEASUREMENT OF IPP 30 
9. PATHOGENESIS OF AUR 36 
 
 
 
 
 
 
 
 ABSTRACT 
 
OBJECTIVE 
To study the prevalence of significant Intravesical Prostatic Protrusion 
(IPP) in patients presenting with acute urinary retention (AUR) due to Benign 
Prostatic Hyperplasia (BPH) and to study the correlation between Intravesical 
Prostatic Protrusion and Prostatic Volume 
METHODS 
We assessed 68 men between the ages 45 to 85 who presented with 
acute urinary retention. Initial assessment included detailed clinical history, 
International Prostate Symptom Score (IPSS) and Quality of Life assessments 
and a transabdominal ultrasonogram to measure Prostate Volume (PV) and 
Intravesical Prostatic Protrusion (IPP). The degree of IPP was determined by 
the distance from the tip of the protrusion to the circumference of the bladder at 
the base of the prostate gland. Patients with IPP >10mm were taken have 
significant IPP and those ≤  10mm was taken to be insignificant. Statistical 
analysis included descriptive analysis and Pearson’s correlation coefficient. 
RESULTS 
Of the 68 patients in our study with resented with AUR, 29 patients 
(42.9%)  had significant IPP.  Mean IPP was 9.81mm with a standard deviation 
of 5.41mm. All patients with significant IPP had a severe IPPS grade. IPP had 
a statistically significant correlation with PV. 
 
 CONCLUSION 
The IPP assessed by transabdominal ultrasound can be used to direct 
appropriate patients to more aggressive treatment strategies like surgery. 
KEYWORDS 
Benign Prostatic Hyperplasia, Intravesical Prostatic Protrusion, Acute Urinary 
Retention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONTENTS 
 CHAPTER        
 PG.NO. 
1. INTRODUCTION…………………………………………  
2. AIMS AND OBJECTIVES………………………………..  
3. REVIEW OF LITERATURE……………………………..  
4. MATERIALS AND METHODS……………….…………  
5. STATISTICAL ANALYSIS………………………………    
6. RESULTS AND OBSERVATIONS………………………  
7. DISCUSSION..…………………………………………….  
8. SUMMARY……………………………………….……….  
9. CONCLUSION…………………………………….………  
10. REFERENCES…………………………………………….  
11. ANNEXURES  
¾ IHEC CERTIFICATE……………………….………  
¾ LIST OF ABBREVATIONS……….……….………  
¾ CONSENT FORM ………………………….………  
¾ PROFORMA ………………………………….…….  
¾ KEY TO MASTERCHART……………………..…..  
¾ MASTERCHART…………………………….………  
  
- 1 - 
 
INTRODUCTION 
 
Benign prostatic hyperplasia (BPH) is one of the most common diseases 
in elderly men. The prevalence of histological BPH increases with age and 
appears in approximately 40% of men aged 50-60 years and in approximately 
90% of men aged more than 80 years(1). Acute urinary retention (AUR) 
represents one of most significant and painful events in the natural history of 
benign prostatic hyperplasia (BPH). Ten per cent of men in their seventies and 
30% in their eighties will have Acute Urinary Retention (AUR) within the next 
five years. Benign prostatic hyperplasia (BPH) is the cause for the AUR in at 
least 65% of men presenting with AUR. Men with AUR often have lower 
urinary tract symptoms (LUTS) for an average of 32 months prior to the 
AUR.(2). 
 
Up to a third of patients undergoing surgical treatment for BPH present 
with acute urinary retention (AUR).(2) Acute urinary retention is associated with 
significant anxiety, discomfort and patient inconvenience. But the symptoms 
and obstruction do not entirely depend on prostate’s size. In contrast, 
Intravesical Prostatic Protrusion (IPP) has been found to correlate with Bladder 
Outlet Obstruction(1). Intravesical Prostatic Protrusion (IPP) is a morphological 
change due to overgrowth of prostatic median and lateral lobes into the bladder 
and may lead to dyskinetic movement of bladder during voiding. Several 
studies have previously demonstrated that the ultrasonographic measurement of 
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IPP is able to detect Bladder Outlet Obstruction (BOO) in BPH patients quickly 
and noninvasively(1). In patients with LUTS, detection of significant IPP can be 
an indication for early surgical intervention.  
 
Hence in this study, we are doing a hospital based study to find out the 
prevalence of Intravesical Prostatic Protrusion and the correlation between 
Intravesical Prostatic Protrusion and Prostate Volume in patients presenting 
with Acute Urinary Retention due to BPH. 
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AIMS AND OBJECTIVES 
 
• To find out the prevalence of significant Intravesical Prostatic Protrusion 
(IPP) in patients presenting with acute urinary retention (AUR) due to Benign 
Prostatic Hyperplasia (BPH) 
 
• To study the correlation between Intravesical Prostatic Protrusion and 
Prostatic Volume 
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REVIEW OF LITERATURE 
INTRODUCTION: 
The Greek word “Prostates” is the origin of the term Prostate and it 
means  ‘ the one that stands before’. Herophilus of Chalcedon coined the term 
around 300BC, after studying its relation to the bladder. The Prostate stands 
before the urinary bladder. 
Benign prostatic hyperplasia (BPH) is one of the most common diseases 
in elderly men.  BPH is defined as prostate enlargement due to epithelial and 
stromal cell proliferations leading to lower urinary tract symptoms and bladder 
outlet obstructions. 
Prevalance of Benign prostatic hyperplasia increases with age. 
Approximately 40% of men aged 50-60 years and about 90% of men aged 
more than 80 years have this condition.(3)  BPH is progressive. Clinical BPH 
with lower urinary tract symptoms appears a long time after the onset of cell 
proliferation. 
 
EMBRYOLOGY:(4, 5) 
The Prostate originates from the primitive endoderm. After regional 
differentiation into the foregut, the midgut and the hindgut, the caudal end of 
the primitive endoderm forms the cloaca. The hindgut opens to the dorsum of 
cloaca, and the ventral cloaca develops into the urinary bladder cranially and 
- 5 - 
the urethra caudally. In males, the prostate gland is formed from the epithelium 
of the prostatic urethra. 
ANATOMY OF THE PROSTATE GLAND(6) 
The prostate is an accessory gland of the male reproductive system. In 
an adult the prostate is classically described to have the size, shape and 
consistency of a large chestnut. It is pyramidal, like a compressed inverted 
cone. While the broad base of the prostate is contiguous with the base of the 
bladder superiorly, the narrowed apex points inferiorly. The prostate has 
anterior, posterior and lateral surfaces. 
In a young adult the normal prostate weighs about 17 to 19 grams. 
Approximate dimensions of the prostate are 4cms transversely, 3cms vertically 
and 2cms sagittally.  
 
Figure 1.  Prostate gland and 
prostatic urethra 
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Extraperitoneal connective tissues envelope the prostate and cover the thin 
anatomic capsule (true capsule) of the gland, and then envelop the proximal 
male urethra. 
The true capsule of the prostate is very thin, covering the gland in toto. 
The extraperitoneal connective tissue forms the false capsule over the true 
capsule. 
The prostate lies below the neck of the bladder in the lesser pelvis, behind the 
lower part of pubic symphysis and the upper part of the pubic arch, in front of 
the rectum. The apex is located above the ischial tuberosities.(7) 
The structures responsible for the fixation of the prostate gland are 
1. The Urinary Bladder   2. The Urogenital Diaphragm 
3. The Prostatic sheath    4. The Fascia of Denonvilliers 
5. The Puboprostatic ligaments(8) 
The Puboprostatic ligaments are a part of the urethral suspensory mechanism 
attaching the membranous urethra to the pubic bone. The suspensory 
mechanism is formed by three anatomic entities in continuity. 
a. The endopelvic fascia between the prostate and the levator ani condenses to 
form the white line. Posteriorly this band is attached to the ischial spine and is 
continuous with the Denonvilliers fascia. Anteriorly it is attached to the pubic 
bone. On either side of the midline, it is continuous with the puboprostatic and 
pubourethral ligaments. The capsule of the gland is attached to the pubic bone 
via the puboprostatic ligament. 
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b. The transverse perineal ligament, formed by the anterior edge of the fascia of 
the urogenital diaphragm, which is continuous with the true capsule of the 
prostate gland. 
c. The pubic arcuate and the transverse perineal ligaments forms the 
inetermediate pubourethral ligament. 
Prostatic Urethra 
The urethral meatus at the apex of the trigone of the urinary bladder is 
the beginning of the Prostatic urethra. The protuberance caused by the 
underlying median lobe of the prostate invaginates into the posterior part of the 
urethral meatus  forming the uvula vesicae and making the opening crescent 
shaped.  
The urethral crest is a ridge on the floor of the posterior urethra between 
the base of the bladder and the membranous urethra. It is wider proximally at 
the bladder neck than distally. 
The verumontanum or seminal colliculus is the expanded portion at the 
middle area of the urethral crest. 
The prostatic utricle is a cypt located in the middle portion of the 
verumontanum. 
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The ejaculatory ducts open on the right and left sides of the 
verumontanum 
The prostatic sinus has the openings of prostatic ductules and ureteral 
glands and is on the right or left side of the urethral crest. 
Surfaces of the Prostate gland 
The prostate has four surfaces-  a posterior surface, an anterior surface 
and two inferolateral surface. 
The posterior surface is convex vertically but flat transversely. 
Denonvilliers fascia separates it from the rectum. A midline groove separates it 
into left and right lobes. This surface is palpated during a digital rectal 
examination. 
Anterior surface is convex and narrow. Approximately 2 cm behind the 
pubis symphysis. The puboprostatic ligaments attach to this surface on either 
sides 
The right and left inferolateral surfaces are attached to the levator ani by the 
white line. 
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Relations of the Prostate gland 
The capsule enclosing the prostate is composed of collagen, elastin and 
abundant smooth muscles. The capsule is on an average 0.5mm thick on the 
posterior and lateral surfaces and blend with the endopelvic fascia on the 
anterior and anterolateral surface. 
Laterally the prostate is related to the pubococcegeal part of the levator ani and 
its overlyning endopelvic fascia. This is also called the lateral prostatic fascia.(9) 
The cavernosal nerves are present within the substance of the lateral prostatic 
fascia, posterolateral to the prostate. Hence this fascia is incised anterior to the 
neurovascular bundle lateral to the prostate to preserve these nerves. (10)These 
fascial layers are clearer during laparoscopy.(11) The neurovascular bundle 
course laterally along the prostate.(12, 13) 
 
Structure of the Prostate gland 
Structurally, the prostate is composed of 70% glandular elements and 
30% fibromuscuular stroma approximately. The fibromuscular stroma is 
continuous with the capsule of the prostate and contains collagen and abundant 
smooth muscle. It invests the glands of the prostate and helps expressing the 
prostatic secretions into the urethra by contracting during ejaculation. 
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Structural zones of Prostate(14) 
The prostate has been divided into four distinct zones based on their relaton to 
the urethra. The glandular area is posterior to the urethra and the fibromuscular 
area is anterior to the urethra. 
The Transition Zone accounts for 5-10% of the glandular tissue. Most common 
site of origin of Benign Prostatic Hyperplasia. Approximately 20% of 
adenocarcinomas of the prostate also originate in this zone. 
 
 
Figure 2. Zones of Prostate 
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 The Central Zone constitutes 25% of the glandular prostatic tissue. It expands 
around the ejaculatory ducts to the base of the bladder in a cone shape. The 
ducts of this zone are found circumferentially around the openings of the 
ejaculatory ducts. 
 The Peripheral Zone forms 70% of the prostatic glandular tissue, covering the 
posterior and lateral aspects of the gland. Its ducts open along the entire length 
of the prostatic urethra. Prostatic cancers commonly (70%) originate in this 
zone. Chronic prostatitis also commonly affect this zone. 
 
Figure 3.  Zonal anatomy of the prostate as described by McNeal  
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 Anterior Fibromuscular Stroma forms one third of the prostatic mass, and is 
non glandular. It is composed of elastin, collagen and smooth and striated 
muscle. 
Lobes of Prostate 
The prostate was earlier described to have six lobes: anterior, posterior, 
median, subcervical, right lateral, and left lateral. This is no longer accepted. 
But clinically the prostate is still referred to as having two lateral lobes and a 
median lobe. The central sulcus that is palpable on rectal examination separates 
the two lateral lobes. The median lobe project into the bladder, in older men. 
Capsules of the prostate gland 
The True capsule is formed by the condensation of the stoma of the 
gland. It is fibromuscular and intimately invests the entire gland. 
The False Capsule also called the prostatic sheath or the periprostatic 
sheath is derived from the visceral layer of the pelvic fascia. Anteriorly it is 
continuous with the fascia of the bladder and the puboprostatic ligament, 
laterally with the arcus tendineus of the endopelvic fascia, posteriorly with the 
denonvilliers fascia and inferiorly with the superior fascia of the urogenital 
diaphragm. 
The prostatic or pudental venous plexus lies between the true and false 
capsules. 
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The Surgical Capsule or the Pathological capsule is formed by the 
compressed peripheral part of the prostate, due to the progressive prostatic 
growth in Benign Prostatic Hyperplasia (BPH). During enucleation of the 
prostate, the adenoma is removed along the pane between the compressed 
peripheral tissue and the adenomatous tissue. The anatomic capsule and the 
peripheral condensed prostatic tissue is left behind. 
 
 
 
 
Figure 4.  Prostate and the Prostatic Urethra 
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Vascular Supply 
 
Figure 5. Surgical Anatomy of 
Prostatectomy 
A. Normal prostate 
B. Prostatic adenoma 
C. Prostatectomy removes 
adenoma but leaves capsule 
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The prostate is primarily supplied by the Inferior vesicle artery. The 
Inferior vesical artery supplies the base of the bladder, distal ureters an the 
prostate. After supplying the base of the bladder it divides into 2 main 
branches. The urethral branch enters the prostatovesicle junction at the 5-o’ 
clock and 7-o’clock position on either side(15), travel inward perpendicular to 
the urethra toward the bladder neck.(16) The urethral artery then turns caudal, 
parallel to the urethra to supply it, the periurethral glands and the transition 
zone. This artery is the main arterial supply for the adenomas in benign 
prostatic hyperplasia. The capsular artery runs posterolateral to the prostate 
with the cavernous nerves. The artery enters the prostate at right angles to 
supply the glandular tissue. 
The blood supply to the seminal vessels and ductus deferens is from the 
artery of the ductus, a branch from the superior vesical artery. 
The periprostatic venous plexus is present between the prostate gland 
and the false capsule. The plexus also receives the deep dorsal penile vein and 
the veins of the bladder base. It communicates to the internal iliac venous 
system and the presacral veins. 
Nerve Supply 
The sympathetic and parasympathetic fibers that come from the pelvic 
plexuses travel to the prostate via the cavernous nerves. The autonomic 
innervations of the prostate arise from the pelvic plexuses formed by the 
- 17 - 
 
parasympathetic, visceral, efferent, and preganglionic fibers that arise from the 
sacral levels(S2-S4). They dilate blood vessels and stimulate secretion from 
glands of the genital system, including the prostate. The sympathetic fibers 
arise from the thoracolumbar levels (L1-L2). The sympathetic fibers cause 
contraction of the smooth muscle and expulsion of seminal fluid. The pelvic 
plexus is located beside the rectum approximately 7 cm from the anal verge, 
with its midpoint located at the level of the tips of the seminal vesicles. The 
neurovascular bundle is located within the periprostatic fascia on the 
dorsolateral surface of the prostate between the rectal wall and the prostate.(17) 
Lymphatic Drainage 
Large intraprostatic lymphatic trunks are formed from the prostatic 
acinus,. They penetrate the prostatic capsule and form the periprostatic 
lymphatic plexus. The periprostatic lymphatic plexus yields lymphatic vessels 
which follow the vascular network of the prostatovesical arteries and drain to 
the internal iliac lymph nodes.(18) The vessels also drain to the presacral lymph 
nodes and, occasionally, to the external iliac lymph nodes. 
Histology 
Glandular epithelium forms seventy per cent of the weight of the 
prostatic mass and thirty per cent is fibromuscular, mainly non-striated. The 
ducts and acini in the glandular part are lined by columnar epithelium and drain 
into the posterior and lateral walls of the prostatic urethra. 
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The three glandular regions of the prostate differ histologically. Ducts 
and acini are lined with secretory epithelium, with a layer of basal cells and 
interspersed endocrine-paracrine cells beneath, in all regions. Small, rounded, 
uniform glands are seen in the peripheral zone. Very large and irregular acini 
are seen in the central and transitional zones. 
The prostate and the urethral and paraurethral glands in the female are 
homologous.(19) 
The prostate gland secretes a milklike alkaline fluid. This fluid is very 
important for the fertilization of the ovum, since sperm within both the ductus 
deferens and vaginal tissue produce fertilization-inhibiting acidity. Guyton113 
stated that prostatic fluid most likely neutralizes the acidity of the fluids of the 
ductus deferens and vagina after ejaculation, enhancing the motility and 
fertility of the sperm. The prostatic fluid also contains citric acid, calcium, 
phosphorus, and other substances 
Age changes in Prostate 
At birth the size of the prostate is small and is mainly made up of stroma 
and a simple duct system. Under the stimulation of maternal estrogens during 
first 6 weeks after birth, the epithelium of the ducts and the prostatic utricle 
undergoes hyperplasia and squamous metaplasia. Then changes are negligible 
till around nine years. Elaboration of duct system by forming side buds and 
increase in gland size happens between 9 and 14 years. 
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Rapid changes during puberty due to the effects of male hormones. 
Rapid growth of follicles happens and the prostate becomes double the 
prepubertal size. Stroma becomes condensed. 
Glandular elements proliferate from 20-30 years of age. 
Prostatic size remains constant between 30-45 years, and involution starts. 
After 45-50 years of age the prostate is either enlarged (BPH) or reduced in 
size (Senile atrophy) 
A healthy male between 50-80 years would have prostate volume of 25-
38cc.(20) 
 
BENIGN PROSTATIC HYPERPLASIA 
A pathological process contributing to LUTS in ageing men. Symptoms 
of BPH were initially believed to be simply due to a mass related increase in 
urethral resistance. Now it is clear that LUTS in older men is mainly due to 
detrusor dysfunction and other systemic medical conditions unrelated to 
prostate bladder unit such as polyuria and sleep disorders. 
LUTS manifest as voiding symptoms and storage symptoms. Voiding 
symptoms have been historically related to bladder outlet obstruction.(21) It is 
however understood that voiding symptoms poorly correlate with underlying 
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pathophysiology.(22) Any other form of obstruction, like, urethral stricture, can 
also produce similar symptoms. Storage symptom or Overactive Bladder 
Syndrome is defined as urgency, frequency, nocturia and urgency incontinence 
correlated with an underlying detrusor overactivity. 
Histologically in BPH there is increased number of epithelial and 
stromal cells in the periurethral region of prostate and is hence called a 
hyperplasia. Epithelial or stromal proliferation or impaired programmed cell 
death leads to cellular accumulation. Other factors that play a role in the 
etiology of the hyperplasia include androgens estrogens, stromal epithelial 
interactions growth factors and neurotransmitters. Another view is that BPH is 
a stem cell disease where dormant stem cells divide and give rise to a type of 
proliferating cells that can synthesise DNA.(23) Normally, cells differentiate, 
has a finite life span, and undergo programmed cell death. In BPH, there is a 
block in this maturation process o that the progression to terminally 
differentiates cell is reduced, reducing the overall rate of cell death causing 
hyperplasia. 
The androgen signalling axis is important in development and maintenance of 
normal prostate and as well as development of BPH. The components 
include(24) 
 Testosterone synthesis in testes and adrenals 
 Conversion of testosterone to dihydrotestosterone by enzyme 5 alpha reductase 
 Transport of dihydrotestosterone to tissues 
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 Binding of dihydrotestosterone to androgen receptor 
Dihydrotestosterone helps in the development of prostate but also cause the 
pathological growth in an adult prostate. 
BPH is also thought to be a form of asymptomatic inflammatory 
prostatitis. Prostatic stromal cells  activate CD4+ lymphocytes and induce 
inflammation.(25, 26) 
Prostatic stroma and epithelial cells maintain a sophisticated 
communication.th stromal component usually inhibits cell proliferation. A 
defect in this component may result in BPH. the process of new gland 
formation in BPH suggests a reawakening of the embryonic process in which 
prostatic stroma induces epithelial cell development.(27) 
Growth stimulatory factors such as FGF-1,2,7,17, vascular endothelial growth 
factors, insulin like growth factors with dihydrotestosterone also play a role in 
the development of BPH.(28) 
BPH also has an inheritable genetic component.(29) 
Epidemiology and Risk Factors: Modifiable risk factors influence the 
natural history of BPH throughout the different stages of its clinical 
progression.(30)  
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Age: 8% of men aged 50-59 years of age and more than 80% for men more 
than 80 years. Prostate volume  increases with age, whereas peak uroflow 
decreases with age.(31) 
Race and socioeconomic status are independently associated with BPH.  
A study concluded that African American men were half as likely to report a 
BPH than a Caucasian American. Surgeries for BPH was more prevalent 
among African Americans.(32) Asians had a lower incidence of prostate cancer 
than whites but incidence of BPH and chronic prostatitis were similar.(33) 
Family History: About 50% of men who underwent prostatectomy for 
BPH, under the age of 60 had an inheritable form of the disease. And only 9% 
of men older than 60 had the familial risk.(34) 
There is a strong correlation between the severity of LUTS and impairment of 
sexual function like erectile dysfunction and ejaculatory disturbances.(35) 
Increase in fibromuscular stroma is a result of sexual activity.(36) The 
pathophysiological events underlying the development of both problems in an 
older male could possibly be similar. The most obvious cause being ischemia 
in both genital and urinary tract organs. 
The frequency of LUTS decreases with physical activity. Studies 
showed that walking, the most prevalent activity, was inversely related to the 
risk for BPH. Walking for 2 – 3 hours per week is had a 25% lower risk of total 
BPH.(37, 38) 
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The pathologist, the urologist, the radiologist and the patient have 
different connotations for the term Benign Prostatic Hyperplasia. Hence BPH 
can be defined in terms of Microscopic BPH, Macroscopic BPH and Clinical 
BPH. 
 
Clinical Manifestations of BPH 
 LUTS 
 Poor bladder emptying 
 Urinary retention 
 UTI 
 Overactive bladder 
 Hematuria 
 Renal insufficiency 
Older men with a variety of lower urinary tract pathologies exhibit similar 
symptoms. These complexes of symptoms are referred to as Lower Urinary 
Tract Symptoms or LUTS. Hence the first challenge is to establish that these 
symptoms are in fact the result of BPH. 
International Prostate Symptom Score (IPSS) 
International Prostate Symptom Score (IPSS) is recommendd as a 
symptom scoring instrument to be used for the baseline assessmentof severity 
of symptoms in men presenting with LUTS.(39, 40) IPSS classifies symptoms a 
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MILD( 0-7), MODERATE (8-19) or SEVERE (20-35). The IPSS can also be 
used as a primary determinant of treatment response or disease progression in 
the follow up period.(41) 
International Prostate Symptom Score (IPSS) Questionnaire [Table 1] 
\Sl. 
No 
 
Symptom 
(In the Past 
Month) 
 
Not at 
all 
 
<1 time 
in 5 
 
Less than 
half the 
time 
 
 
About 
half the 
time 
 
More 
than 
half the 
time 
 
Almost 
always 
1 Incomplete 
Emptying 
 
How often have 
you had the 
sensation of not 
emptying 
your bladder? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
2 Frequency 
 
How often have 
you had to 
urinate less than 
every two hours? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
3  
Intermittency 
How often have 
you found 
you stopped and 
started again 
several times 
when you 
urinated? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
4  
Urgency 
How often have 
you found it 
difficult to 
postpone 
urination? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
5        
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Weak Stream 
How often have 
you had a weak 
urinary stream? 
0 1 2 3 4 5 
6  
Straining 
How often have 
you had to strain 
to start urination? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
None 1 time 2 times 3 times 4 times 5 times 
7  
Nocturia 
How many times 
did you typically 
get up at night to 
urinate? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
Total IPSS  
 
      
 
 
Quality of life due to urinary symptoms [Table 2] 
 
Quality of Life 
Due to 
Urinary 
Symptoms 
 
Deligh
ted 
 
Pleased 
Mostly 
satisfied 
Mixed- 
about 
equally 
satisfied and 
dissatisfied 
Mostly 
dissatisf
ied 
Unhappy Terribl
e 
 
If you were to 
spend the rest 
of your life 
with your 
urinary 
condition just 
the way it is 
now, how 
would you feel 
about that? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
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Physical examination 
Digital rectal examination and focused neurological examination must 
be performed. The external genitalia must also be examined and a meatal 
stenosis or a palpable urethral mass must be excluded. Abdominal examination 
excludes a palpable overdistended bladder. The DRE and focused neurological 
examination detects a prostate or a rectal malignancy and evaluate anal 
sphincter tone. The presence of induration or a nodule is important and must be 
correlated with serum PSA, and prostate biopsy must be taken if warranted. 
 
Grading of the size of prostate by   DRE(43) [Table 3] 
Grade             DRE finding 
Normal Prostate encroaches 0-1cm into rectal lumen 
Grade 1 Prostate encroaches 1-2cm into rectal lumen 
Grade 2 Prostate encroaches 2-3cm into rectal lumen 
Grade 3 Prostate encroaches 3-4cm into rectal lumen 
Grade 4 Prostate encroaches >4cm into rectal lumen 
 
 
- 27 - 
 
DRE helps to assess the approximate size of the gland, and is important 
to select the appropriate treatment. Prostate size does not precisely correlate  
with symptom severity, degree of urodynamic obstruction or treatment 
outcome.(42) Ultrasonography is more accurate than a cystourethroscopy in 
measurement of the prostate size. The larger a gland and a higher PSA is 
associated with a greater risk of progression of BPH.(3, 43) 
Urinalysis should be done to rule out urinary tract infection and 
hematuria. A non-BPH cause of symptoms must be suspected in either case. 
Urine cytology is important in men with severe irritable symptoms and dysuria, 
especially if they have a history of smoking. The possibility of carcinoma 
bladder should not be overlooked. 
Serum creatinine measurement: BPH patients with renal insufficiency 
are at increased risk of postoperative complications. Patients with renal 
impairment have a 25% risk while those without have a 17% risk.(44) Elevated 
creatinine levels should be an indication for ultrasonography of the upper 
urinary tract. 
Transabdominal sonography of the prostate helps to measure prostatic 
urethral length, size and configuration of the median lobe of the prostate and 
information about the physiology of bladder outlet obstruction that is important 
in planning the treatment of bladder outlet obstruction. A 3.5 to 5 MHz 
transducer is most commonly used. 
- 28 - 
 
The probe is angled beneath the pubic bone. The largest diameter of the 
prostate is identified in the transverse plane. The transverse width and height is 
measured. The true sagittal image of the prostate is obtained by rotating the 
transducer 90 degrees clockwise. The transducer is fanned until thee midline is 
located, by identifying the v-shaped indentation at the bladder neck. 
Depending on the degree of the hypertrophy of the prostate, and the presence or 
absence of an enlarged median lobe of the prostate, the ‘v’ may be more or less 
apparent and be located more or less anterior or posterior. The sagittal 
measurement is made from the bladder neck to the apex of the prostate gland. 
The degree of protrusion of prostate into the bladder has some predictive 
value for bladder outlet obstruction. Intravesical prostatic protrusion (IPP) 
correlates well with urodynamic evaluation of bladder outlet obstruction. IPP is 
measured by drawing a line corresponding to bladder base on a sagittal view 
and perpendicularly measuring the distance from the bladder base to the 
greatest protrusion of the prostate into the bladder. 
Trans abdominal ultrasonogram yields limited information in case the 
bladder is empty. A full bladder is required for identification of distal ureteric 
obstruction, bladder calculus, and bladder tumors. Prostate morphology and 
volume assessment is easier when the bladder is full. It may be difficult to 
evaluate the pelvis in patients with a protuberant abdomen. 
Prostate volume is calculated using the formula  
Prostate Volume (ml) = π/6 x width (cm) x height (cm) x length (cm) 
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Figure 7.   Prostate Volume Measurement 
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Transrectal ultrasonogram (TRUS) 
TRUS  has both diagnostic and therapeutic functions. It can be used for 
the diagnosis and evaluation of prostate abnormalities like Benign Prostatic 
Hyperpalsia, prostate cancer, prostate abscess, and prostatic calculus. It has 
become a mainstay in ultrasound guided prostate biopsies, Brachytherapy and 
high intensity focused ultrasonography. Contraindications for TRUS are acute 
painful perineal diseases and bleeding diatheses.  7- MHz transducer is most 
commonly used and can produce both sagittal and axial images. 
Serum Prostate Specific Antigen 
Although serum PSA assay is widly accepted as a prostate cancer tumor 
marker, it is organ specific and not disease specific. There  is an overlap of 
Figure 8.  IPP is measured on a sagittal view by measuring the distance from the bladder base 
to the greatest protrusion of the prostate into the bladder perpendicularly 
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serum PSA levels in men with cancer and those with benign disease. PSA may 
also be elevated in prostatic inflammation. 
A PSA assay and a DRE increase the rate of detection of prostate 
cancer. Prostate cancer and BPH may co exist. 
PSA is found in low concentrations in serum, normally. PSA is found in 
both bound and unbound forms in the serum. It is bound to antiproteases and 
macroglobulins. The free PSA is immunodetectable by current assays. 
The sensitivity of PSA testing is 67.5 - 80% and the specificity is 60 – 
70% in detecting prostate cancer if the levels are higher than 4.0ng/mL. 
 
Postvoid residual urine volume assessment.  
Post void residual urine volume is the amount of urine retained in the 
bladder immediately after the completion of micturition. Normally, 78% of 
men have a PVR volume <5ml and almost 100% have < 12 ml. 
Uroflowmetry.  
It is electronic measurement of urinary flow rate throughout the course 
of micturition. 
Complications of BPH 
Many of the complications of BPH are rare. 
- 32 - 
 
Recurrent previous UTIs are the main indication for surgical 
intervention. Increased amount of residual urine predisposed to development of 
UTI. 
Bladder stone development in BPH is rare and is investigated for in case 
of hematuria or stuttering of urination. 
Bladder decompensation is the progression from normal mucosa to 
trabeculations, development of cellules and diverticula and ultimately detrusor 
muscle failure, and it is a rare possibility. 
Urinary incontinence  may de due to PBH secondary to over distension 
of bladder (Overflow incontinence) or due to detrusor instability (Urge 
incontinence).  
Upper Urinary Tract Deteriortion and Azotemia.: Development of renal 
failure in asymptomatic patients is termed silent obstruction or silent 
prostatism. This condition is both rare and important. Renal Azotemia is 
defined as doubling of serum creatinine concentration from baseline. 
Gross hematuria in patients with BPH develops without any other 
identifiable cause. Recent studies suggest that microvessel density is higher in 
patients predisposed to hematuria 
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ACUTE URINARY RETENTION (AUR) 
Acute Urinary Retention is one of the most significant complication or 
long term outcomes resulting from BPH. In the past it was considered an 
immediate indication for surgery. Even today patient who fail to void after an 
attempt of catheter removal undergo surgery. The etiology of acute urinary 
retention is poorly understood and obstructive, myogenic and neurogenic 
causes are considered to play a role. Prostatic infarction has been suggested an 
underlying event in causing AUR. 
The impact that acute urinary retention can have on the quality of life is 
comparable to that of an attack of renal colic(45). For a patient with BPH, even a 
single episode of urinary retention is significant. It is characterized by the 
inability to void, increasing pain, and need for catheterization. Follow-up visits 
to the doctor is required with an attempt of trial voiding without catheter. If 
trial voiding fails, the patient may require surgery. This  is a painful and time-
consuming process. The risk of recurrent retention was 56%–64% within 1 
week of the first episode as per the previously available data.(46-48) 
The risk of acute urinary retention in a patient with BPH is higher, when 
compared to the general population. The risk factors are PSA, prostate volume, 
maximum flow rate, and symptom severity. These should be kept in mind when 
counselling patients with benign prostatic hyperplasia who are planned for 
medical management. 
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Etiology of AUR.  
a. Prostatic inflammation -  
An event of prostatic inflammation is usually the trigger for the first 
episode of AUR. According to Kefi et al.,29% of patients who presented with 
LUTS had prostatic inflammation but 54% of men who presented with AUR 
had prostatic inflammation.(49) Both increased size of prostate and raised PSA 
levels were considered as predicting factors for AUR in BPH. There is rapid 
progression of symptoms in these patients and they are more likely to undergo 
surgery when compared with those without inflammation.(50) The cause for 
inflammation in BPH has not been clearly identified. The large amount of 
CD4(+) T lymphocytes present suggest the possibility of  autoimmune 
etiology. This was also confirmed by increased levels of inflammatory 
cytokines (IL-15 and IFN-gamma)(51) which are released by smooth muscle 
cells and T cells . 
 
 
b. Prostatic infarction (52) 
Infarction of prostate can cause AUR.  Spiro and colleagues compared 
the prostatectomy specimens between patients who presented with AUR and 
those with symptoms alone. 85% of prostates removed for AUR showed 
infarction  but only 3% of patients with symptoms alone had prostatic 
infarction.(53) Infection, trauma during instrumentation compromises 
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intraglandular blood supply and can cause prostatic infarction .The exact 
mechanism causing prostatic infarction has not been determined.  
 
 
 
 
 
 
 
 
 
                                   (54) 
 
 
In a  similar study comparing the prostatectomy specimens of thirty five 
men with AUR and thirty five men without urinary retention done by Anjum 
and colleagues they found that three percent of men with AUR showed 
infarction of prostate and only 1.9% men showed infarction without 
retention.(55) Conclusive studies that shows infarction to be the cause of acute 
urinary retention  are pending. 
Prostatic infarction 
 
 
Swelling of prostate 
 
 
Rise in intraluminal prostatic 
urethral pressure 
 
 
Increased efferent activity of 
alphaadrenergic nerves 
 
 
Intraurethral pressure further get 
increased 
 
 
Development of AUR 
Figure 9. A proposed 
model for AUR due to 
prostatic infarction by 
Abes House et al  (54) 
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c. Alteration in Stromal and Epithelial ratio 
Study comparing the specimens from paients with AUR and patients 
with LUTS only showed that the former group had increased epithelial 
component (71%) as compared to the latter (60%). 
The disruption in the blood supply of the gland caused by the alteration in ratio 
of epithelial and stromal growth may ultimately result in infarction of prostate 
and finally cause acute urinary retention. 
 
Finasteride , 5 alpha reductase inhibitor has its acts mainly on the epithelial 
component of the prostate gland. It decreases the incidence of acute urinary 
retention .This supports the fact that alteration in Stromal and Epithelial ratio 
with increased epithelial component may cause AUR. 
 
d. Genitourinary instrumentation   
Acute urinary retention can be caused by diagnostic procedures like 
cystoscopy, ureteroscopy, prostatic biopsy and in the immediate post-operative 
period. This is mostly due to irritation of genitourinary tissues and also 
sometimes by hematuria. The use of flexible cystoscopy has decreased the 
incidence of acute urinary retention probably due to lesser trauma and lesser 
irritation while using a flexible scope. Trans rectal biopsy of prostate using 
bigger tru-cut needles may cause acute urinary retention. This is usually due to 
the trauma to the prostatic tissues with hematoma and swelling causing urinary 
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retention. Clots associated with hematuria can also cause urinary retention. 
Smaller sized needles used under TRUS guidance rarely produce acute urinary 
retention.(56) AUR following ureteroscopy is usually due to bladder irritation. 
 
e. Postoperative AUR  
The occurrence of AUR in the post operative period is independent of 
the presence or absence of BPH. Causes of postoperative AUR include 
Anesthesia, analgesia, pain , suppressed consciousness and intravenous fluids. 
An IV infusion of more than 750ml and advanced age are found to be the better 
predictors of AUR in post operative period. This was proposed by Hawa et al. 
 
f. Constipation  
Constipation may be considered a cause for acute urinary retention in 
the absence of fecal impaction, neurological disease,or bladder outlet 
obstruction. The Alfuzosin in Acute Urinary Retention (ALFAUR) study 
concluded that, though the results of trial voiding whether failed or successful 
was independent of the history of constipation, patients with constipation are at 
increased risk for recurrent urinary retention and may need surgical 
intervention for BPH. 
 
g. Stroke (CVA)  
Impaired bladder emptying is one of the neurological sequelae of stroke and 
can precipitate Acute Urinary Retention. 
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h. Alcohol ingestion  
Suppression of the Central nervous system associated with fluid 
overload, may cause acute urinary retention. 
 
The presence or absence of BPH does not alter the occurrence of AUR 
in stroke and also in alcohol ingestion. 
 
i. Drugs 
Anti cholinergic agents like drugs used for depression, allergies 
,Parkinson's disease etc. produce AUR by detrusor relaxation. Alpha agonists, 
like those in over-the-counter cold remedies cause urinary retention by 
increasing bladder outlet resistance.  
Athanasoupolos et al. concluded that, in urodynamically proven bladder outlet 
obstructed patients, tolterodine and an alpha antagonist can be safely 
administered together without developing of urinary retention.(57) 
Reynard et al. concluded that anticholinergic drugs can safely be used in 
patients with BPH .The risk of developing urinary retention is minimal and the 
only effect that patients had was a minimal raise in post-void residual urine 
volume.(58) 
BPH patients patients with more irritative LUTS and low post-void residual 
urine volume are ideal candidates who can be given anticholinergic drugs 
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Non-steroidal anti-inflammatory drugs (NSAIDS) -NSAIDs inhibit 
prostaglandin synthesis (PGE2) and hence the detrusor contractions caused by 
PGE2, and cause urinary retention.(59) Patients who have started taking 
NSAIDs recently are at highest risk. NSAIDS cause AUR at doses equal to or 
higher than the recommended daily dose. No association has been noted 
between past use of NSAIDs and AUR. 
 
j. Urinary tract infection (UTI)  
Infection produces acute inflammation and edema of the bladder 
mucosa. Urinary retention results from mucosal thickening. This may resolve 
treatment of infection with appropriate antibiotics. A UTI may precipitate or 
complicate  an AUR. 
 
k. Bladder overdistension(60)  
Patients who underwent regional anesthesia, prolonged labour or long 
duration surgery urinary retention is usually unnoticed and also incompletely 
treated.         This will result in prolonged overdistended bladder in a short 
duration ultimately causing temporary neurogenic detrusor decompensation 
(myogenic bladder damage). Bladder sensation is either decreased or absent. In 
these patients retention symptoms are obscured and treatment is also not started 
promptly. 
l.  Excessive fluid intake 
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Prostatomegaly can lead to bladder outflow obstruction by occluding the 
urethral lumen. Acute urinary retention can occur in men with prostatomegaly 
when they drink large volume of fluids or refrain from emptying his bladder for 
a longer period than usual. Detrusor muscle stretches. The combination of poor 
detrusor muscle function and outflow obstruction lead to AUR. 
 
m. Bed rest 
Decreased mobility and increased bed rest – may be considered one of the 
reasons for post operative urinary retention.(61) 
 
n. Sexual activity 
o. Debility 
 
'Spontaneous' vs 'Precipitated' Acute Urinary Retention   
Acute Urinary Retention can be classified in to spontaneous AUR and 
precipitated AUR. Although this classification is not followed routinely, it is 
helpful in assessing the prognosis of patients clinically. 
A Precipitated AUR is one where the inability to void is associated with a 
triggering event.For example, Post operative ( pelvic or prostate related 
surgeries), anticholinergic or alpha agonist drug intake or following aesthesia. 
A spontaneous AUR occurs without any triggering events.(62, 63) 
On comparison, 15% with spontaneous AUR type, experienced a second event 
of retention, whereas only 9% of men with precipitated type AUR had a second 
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episode of AUR. 75% of men with spontaneous AUR underwent surgery, 
whereas 26% of patients with precipitated type underwent surgery later.(63) 
 
In all cases of AUR ,initial evaluation should exclude BPH as a cause 
for retention. In majority of patients, BPH is the cause and patient should be 
offered an alpha blocker followed by trial voiding without catheter after a 
period of three to five days. However in precipitated type, the factor which had 
precipitated was found to alter the long term result, hence it should also be 
properly given importance in long term management.(64) 
 
Predicting factors of Acute Urinary Retention 
In BPH, the predicting factors for AUR can be categorized in to baseline 
and dynamic variable factors. 
Base line variable factors are - 
1. Advanced age 
2. Lower urinary tract symptom severity 
3. Decreased peak flow rate 
4. Raised post void residual volume of urine (PVR) 
5. Enlarged prostate6. Increased PSA level 
7. Previously conservatively treated AUR 
 
Dynamic variable factors are 
1. > 4 points deterioration of IPSS, 
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2. During treatment, worrisome score >3 points 
3. Raising post void residual volume of urine (PVR) 
4. Refractory to alpha blockers 
 
Management of BPH 
Treatment options for patients with moderate to severe symptoms of BPH 
 
Watchful waiting: 
When complications of treatment are perceived to be greater than 
severity of symptoms. Severity of symptoms may be improved by reducing 
total fluid intake especially before bedtime, moderating caffeine and alcohol 
intake. Watchful waiting is recommended when the IPSS is <7, where the 
symptoms are mild and do not interfere with daily activities. 
 
Medical Therapies: 
The aim of an intervention ia almost all patients with BPH is to relieve 
symptoms and improve quality of life, the lower morbidity associated with 
medical therapy is important in deciding treatment modality. 
This should ideally be reserved for patients who have bothersome symptoms 
that negatively affect quality of life. 
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Combination therapy with a selective 5-apha reductase and an alpha-blocker 
has greater benefits over either drug as monotherapy in reducing the risk 
clinical progression. 
 
 
Alpha-Blockers 
-Alfuzosin    -Terazocin 
-Doxazosin    -Silodosin 
-Tamsulosin 
 
5-Alpha-Reductase inhibitors (5-ARIs) 
-Dutasteride 
-Finasteride 
Combination therapy 
Alpha-blocker + 5-ARI 
Alpha-blocker + anticholinergics 
Surgical therapies 
Minimally invasive surgical therapy 
Transurethral needle ablation 
Transurethral microwave therapy 
 
Intraprostatic stents are used in patients who are unfit for surgery, and in whom 
the alternative would be a lifetime of indwelling urethral catheters 
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Prostatectomy 
 Open Prostatectomy 
 Transurethral holmium laser ablation of the prostate (HoLAP) 
 Transurethral holmium laserenucleation of Prostate (HoLEP) 
 Holmium laser Resection of Prostate (HoLRP) 
 Photoselective vaporization of prostate (PVP) 
 Transurethral incision of Prostate (TUIP) 
 Transurethral Vaporization of Prostate (TUVP) 
 Transurethral resection of Prostate (TURP) 
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MATERIALS & METHODS 
 
The study was a descriptive study conducted on 68 patients  presented 
with Acute Urinary Retention to the department of General Surgery at Sree 
Mookambika Institute of Medical Sciences, Kulasekharam during a time period 
of 18 months. The study was initiated after obtaining ethical clearance from the 
institutions ethical clearance committee.  
The patients who met the pre-defined criteria and gave an informed consent 
between the time periods June 2016-November 2017are included in the study 
after explaining the procedure and getting the consent. The criteria were: 
 
Inclusion criteria: 
• All patients of BPH presenting with Acute Urinary Retention 
• Men of age group 45-85 years 
 
Exclusion criteria: 
Patients with 
 Bladder Calculus 
 Neurological conditions (Parkinson’s Disease or CVA which predispose the 
patient to neurogenic bladder) 
 Documented malignancy 
After acceptation of the thesis by the ethics committee, an informed consent 
will be obtained from those patients presenting with Acute Urinary Retention, 
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to General Surgery OPD of Sree Mookambika Institute of Medical Sciences, 
who fulfil the criteria of inclusion. Relevant clinical data (demographic-age, 
sex, place, occupation) including history will be obtained from the patient. 
 
History taking: 
Proforma is used for documenting age / sex / address / clinical 
information / symptoms / predisposing factors and any previous history of 
treatment. An International Prostate Symptom Score (IPSS) questionnaire is 
also provided and the severity of symptoms is graded. 
 
Measurements: 
Intravesical Prostatic Protrusion and Prostatic Volume will be assessed 
by Trans-abdominal Ultrasonogram and will be carried out in the Department 
of Radiodiagnosis, Sree Mookambika Institute of Medical Sciences, 
Kulasekharam. IPP was measured the shortest distance connecting the 
protruded end of the prostate into the bladder base on the bladder neck in the 
sagittal plane, which reflects the maximal longitudinal length of the prostate as 
suggested by Nose et al. 
• IPP < 10mm is not considered significant. 
• IPP > 10mm is considered significant 
• Normal Prostate Volume: 15 – 20 cc. 
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Correlation of the IPP with volume of the prostate and the prevalence of 
significant IPP in patients presenting with Acute Retention of Urine was 
calculated. 
SAMPLING: 
a) Sampling Technique : CONVENIENT SAMPLING 
b) Sample size of each group: Only one Group (n = 68) 
c) Total Sample size of the study: 68 
d) Scientific basis of sample size used in the study: 
N = 4pq/D2 
p - Prevalence  = 59.5 (12) 
q = (100-p) 
  = 100-59.5 
  = 40.5 
D = 20% of p 
    = 59.5 x 20 /100 
    = 11.9 
N = (4 x 59.5 x 40.5) / (11.9)2 
    = 68.06    (Sample size rounded off to 68) 
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STATISTICAL ANALYSIS 
 
Data collected were entered in Microsoft Excel 2010. Statistical analysis was 
done using SPSS trial version 20.0. Descriptive analysis of the data (Mean and 
Standard Deviation) together with Pearson’s correlation coefficients were used 
to assess the relationships between IPP, PV and IPSS. 
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OBSERVATIONS AND RESULTS  
 
AGE DISTRIBUTION 
The distribution of age in the study population ranges from 45 to 85 years. The 
mean age of study participants were 65.94 years with a SD of 8.271 years. 
 
Distribution of age of participants [Table 4] 
 
 
 
 
 
 
Half of the study participants were 60-69 years of age group (50%), followed 
by 70-79 years of age group (25%). 
 
 
 
 
Age characteristics Value 
Minimum 
Maximum 
Mean 
Standard deviation 
45 
85 
65.94 
8.271 
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Age distribution in the study population [Table 5] 
Age group Frequency Percent 
40-49 1 1.5 
50-59 10 14.7 
60-69 34 50 
70-79 17 25 
80-89 6 8.8 
Total 68 100 
 
Age of the study participants [Graph 1] 
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PROSTATE VOLUME  
The distribution of prostate volume in the study population ranges from 23 to 
105 cu cm. The mean prostate volume of study participants were 64.10 cu cm 
with a SD of 23.255 cu cm. 
Distribution of prostate volume [Table 6] 
 
 
 
 
 
 
INTRAVESICAL PROSTATIC PROTRUSION (IPP) 
The distribution of intravesical prostatic protrusion (IPP) in the study 
population ranges from 4 to 23 mm. The mean IPP of study participants were 
9.81 mm with a SD of 5.412 mm. 
Distribution of IPP [Table 7] 
 
 
 
 
 
  
Prostate volume Value (cu cm) 
Minimum 
Maximum 
Mean 
Standard deviation 
23 
105 
64.10 
23.255 
IPP Value 
Minimum 
Maximum 
Mean 
Standard deviation 
4 
23 
9.81 
5.412 
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PREVALENCE OF SIGNIFICANT INTRAVESICAL PROSTATIC 
PROTRUSION (IPP) 
Distribution of prevalence of significant IPP [Table 8] 
Significant IPP (>10mm) Frequency Percent 
Yes 29 42.6 
No 39 57.4 
Total 68 100 
 
Prevalence of significant intravesical prostatic protrusion (IPP) 
[Graph 2] 
 
In our study, significant Intravesical Prostatic Protrusion was present in 42.6% 
of patients who presented with Acute Urinary Retention  
 
42.6% 
57.4% 
Yes
No
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PROSTATE GRADE 
35.3% of the study participants have grade III prostatomegaly (60-90 gm) and 
30.9% of the study participants have  grade II prostatomegaly (40-60 gm). 
 
Distribution of prostate grade [Table 9] 
 
Prostate grade Frequency Percent 
I (20-40 gm) 13 19.1 
II (40-60 gm) 21 30.9 
III (60-90 gm) 24 35.3 
IV (>90 gm) 10 14.7 
Total 68 100.0 
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Prostate grade in the study population [Graph 3] 
 
 
 
 
 
In our study, 19% of the patients who presented with Acute Urinary 
retention was found to have only a grade I prostate (<40cc). 31% of the patients 
had grade II prostate, 35% of the patients grade III prostate and 14% patients 
grade IV prostate 
 
 
 
 
19.1% 
30.9% 35.3% 
14.7% 
I
II
III
IV
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Distribution of Prostate grade among patients with significant IPP 
[Table 10] 
 
 
Prostate 
grade 
Significant IPP 
>10mm ≤10mm 
Freq. % Freq. % 
I 0 0 13 100 
II 0 0 21 100 
III 19 79.2 5 20.8 
IV 10 100 0 0 
 
Distribution of IPP in different age groups [Table 11] 
 
Prostate 
grade 
IPP 
>10mm ≤10mm 
Freq. % Freq. % 
40-49 0 0 1 100 
50-59 3 30 7 70 
60-69 11 32.4 23 67.6 
70-79 10 58.8 7 41.2 
80-89 5 83.3 1 16.7 
 
 
All patients with grade IV prostate had significant IPP and significant IPP was 
most prevalent in patients of the oldest age group (80-89 years).  
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IPSS COMPONENTS 
INCOMPLETE EMPTYING 
Distribution of incomplete emptying [Table 12] 
Incomplete emptying Frequency Percent 
<1 time in 5 7 10.3 
Less than half the time 24 35.3 
About half the time 14 20.6 
More than half the time 13 19.1 
Almost always 10 14.7 
Total 68 100.0 
 
 
In our study, about 35.3% of patient gave a history of incomplete micturition 
less than half the time, and 14% had the complaint almost always. 
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Incomplete emptying in the study population [Graph 4] 
 
 
 
 
 
 
 
 
10.3% 
35.3% 
20.6% 
19.1% 
14.7% 
0
5
10
15
20
25
30
35
40
<1 time in 5 Less than half the
time
About half the
time
More than half the
time
Almost always
% 
- 58 - 
FREQUENCY 
Distribution of frequency [Table 13] 
Frequency Frequency Percent 
Less than half the time 3 4.4 
About half the time 19 27.9 
More than half the time 30 44.1 
Almost always 16 23.5 
Total 68 100 
 
Frequency in the study population [Graph 5] 
 
In our study about 44% of the patients had increased frequency of micturition 
more than half the time. 
4.4% 
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INTERMITTENCY 
Distribution of intermittency [Table 14] 
Intermittency Frequency Percent 
Less than half the time 20 29.4 
About half the time 28 41.2 
More than half the time 18 26.5 
Almost always 2 2.9 
Total 68 100 
 
Intermittency in the study population [Graph 6] 
 
In our study, about 41% of the patients had intermittency while voiding about 
half the time while 27% of the patient had the complaint more than half the 
time. 
 
29.4% 
41.2% 
26.5% 
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Less than half the time
About half the time
More than half the time
Almost always
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URGENCY 
Distribution of urgency [Table 15] 
Urgency Frequency Percent 
Less than half the time 15 22.1 
About half the time 21 30.9 
More than half the time 22 32.4 
Almost always 10 14.7 
Total 68 100 
 
Urgency in the study population [Graph 7] 
 
In our study about 32% of the patients complained of weak urinary stream 
more than half the time and about 31% had the complaint about half the time. 
22.1% 
30.9% 
32.4% 
14.7% 
Less than half the time
About half the time
More than half the time
Almost always
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WEAK STREAM 
Distribution of weak stream [Table 16] 
Weak stream Frequency Percent 
About half the time 19 27.9 
More than half the time 30 44.1 
Almost always 16 23.5 
Total 68 100.0 
 
Weak stream in the study population [Graph 8] 
 
About 23% had a weak stream of urine almost always and the rest of the 
patients had the complaint atleast half the time. 
 
27.9% 
44.1% 
23.5% 
About half the time
More than half the time
Almost always
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STRAINING 
Distribution of straining [Table 17] 
Straining Frequency Percent 
About half the time 32 47.1 
More than half the time 25 36.8 
Almost always 11 16.2 
Total 68 100 
 
Straining in the study population [Graph 9] 
 
About 36% of the patients in our study had to strain to void urine more than 
half the time and 47% had the complaint about half the time. 
47.1% 
36.8% 
16.2% 
About half the time
More than half the time
Almost always
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NOCTURIA 
Distribution of nocturia [Table 18] 
Nocturia Frequency Percent 
3 times 38 55.9 
4 times 23 33.8 
5 times 7 10.3 
Total 68 100 
 
Nocturia in the study population [Graph 10] 
 
In our study, all our patients had to void more than 3 times a night. 
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QUALITY OF LIFE 
More than half of the study participants are unhappy (63.2%).  
Distribution of quality of life [Table 19] 
 
Quality of life Frequency Percent 
Mostly dissatisfied 25 36.8 
Unhappy 43 63.2 
Total 68 100 
 
Quality of life in the study population [Graph 11] 
 
 
 
 
36.8% 
63.2% 
Mostly dissatisfied
Unhappy
- 65 - 
 
IPSS 
The distribution of IPSS in the study population ranges from 17 to 33. The 
mean IPSS of study participants were 24.32 with a SD 4.692. 
 
Distribution of IPSS [Table 20] 
 
 
 
 
 
 
 
 
 
 
 
 
 
IPSS Value 
Minimum 
Maximum 
Mean 
Standard deviation 
17 
33 
24.32 
4.692 
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IPSS GRADE 
All patients who presented with Acute Urinary Retention had atleast moderate 
grade of IPSS. 80.9% of the study population have severe IPSS grade. 
Distribution of IPSS grade [Table 21] 
IPSS grade Frequency Percent 
Moderate 13 19.1 
Severe 55 80.9 
Total 68 100 
 
 
IPSS grade in the study population [Graph 12] 
 
 
 
 
 
 
19.1% 
80.9% 
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Severe
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PREVIOUS AUR 
23.5% of the study population have had a previous AUR. 
Distribution of previous AUR [Table 22] 
Previous AUR Frequency Percent 
Yes 16 23.5 
No 52 76.5 
Total 68 100 
 
 
 
Previous AUR in the study population [Graph 13] 
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PUS CELLS IN URINE ROUTINE EXAMINATION 
Half of the study participants (51.5%) have pus cells in urine routine 
examination. 
Distribution of pus cells in urine routine examination [Table 23] 
Pus cells in urine routine 
examination 
Frequency Percent 
Yes 35 51.5 
No 33 48.5 
Total 68 100 
 
Pus cells in urine routine examination [Graph 14] 
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PROSTATE TENDERNESS 
Only 10.3% (7) have prostate tenderness. 
Distribution of prostate tenderness [Table 24] 
Prostate tenderness Frequency Percent 
Yes 7 10.3 
No 61 89.7 
Total 68 100 
 
Prostate tenderness in the study population [Graph 15] 
 
 
10.3% 
89.7% 
Yes
No
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CORRELATION BETWEEN INTRAVESICAL PROSTATIC 
PROTRUSION AND PROSTATIC VOLUME 
There is strong positive correlation (0.878) between intravesical prostatic 
protrusion and prostatic volume 
 
Correlation between intravesical prostatic protrusion and prostatic 
volume [Table 22] 
 
Prostatic volume IPP 
Prostatic 
volume 
Pearson 
Correlation 
1 0.878** 
Sig. (2-tailed)  0.000 
N 68 68 
IPP Pearson 
Correlation 
0.878** 1 
Sig. (2-tailed) 0.000  
N 68 68 
 
** Correlation is significant at the 0.01 level (2-tailed). 
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DISCUSSION 
 
 
Although Benign Prostatic Hyperplasia is not a life threatening disease it 
adversely affects the quality of life. Most patients seek treatment to be relieved 
of bothersome symptoms.(65) Benign Prostatic Hyperplasia is a common cause 
of Bladder outlet obstruction and later causes Acute urinary retention as a long 
term consequence. The impact of acute urinary retention on patients’ health 
related Quality of life is comparable to an attack of renal colic(45). Urodynamic 
studies are gold standard in the diagnosis of Bladder outlet obstruction. But 
since it is an invasive, time consuming and expensive procedure its clinical 
applications have been limited. Several non-invasive indices have been tried to 
obtain similar information in an objective to direct more aggressive therapy to 
those patients who are most likely to benefit from such approach.(66) 
IPSS is a simple tool in the evaluation of BPH and worsening scores warrant 
intervention. But it has a poor correlation with BOO.(66) 
Since Nose et al. described the clinical implications of IPP there has been many 
studies related to IPP.(67) 
Kim, et al. in 2010 concluded in their study that IPP grade was statistically 
significantly related to both overactive bladder and acute urinary retention.(68) 
Hossain, et al. in 2010 concluded that, PV and IPP measured through 
transabdominal USG are non-invasive, accessible method that significantly 
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correlates with BOO in patients with BPH and correlation of IPP is stronger 
than that of PV.(1)  
Keqin, et al. in 2007 did a study on clinical significance of IPP in patients with 
BPH and concluded that BOO and impaired detrusor function were more 
severe in patients with significant IPP.(69) 
Shiong Lee, et al. in 2010, concluded that IPP is a quick non invasive test to 
predict clinical progression in BPH and that higher grade IPP is associated with 
a higher risk of clinical progression of BPH.(70) 
Lim, et al. in 2006 while comparing IPP, PV and serum PSA in evaluation of 
BOO, concluded that PSA, PV and PSA correlate well with one another but 
IPP predicts BOO better than PSA or PV.(66) 
Gyawali, et al. in 2008 while studying the relationship with IPP and PV, 
concluded that IPP assessed by trans abdominal USG is more accurate than PV 
in evaluating bothersome symptoms in men with BPH.(65) 
Chia, et al. in their study on correlation of IPP with BOO, concluded that IPP 
assessed by transabdominal USG is better and more reliable predictor of BOO 
than a pressure flow study.(71) 
Cumpanas, et al. In 2011 concluded that men with IPP exceeding 10mm were 
more frequently poor responders to medical treatment with Tamsulosin among 
patients with Lower Urinary Tract Symptoms due to BPH, PV<40ml, PSA < 
1.5ng/ml.(72) 
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Mariappan, et al. in 2006, found out that among white men presenting with 
AUR, a trial without catheter is more likely to fail in patients with intravesical 
prostatic protrusion larger than 10mm.(73) 
Franco, et al. in their study concluded that Suprapubic USG of detrusor wall 
thickness and IPP is a simple, non-invasive accurate system to assess bladder 
prostatic obstruction in patients with LUTS due to BPH(74). 
Lee, et al. in his study found that IPP showed significant correlation with 
storage symptoms and could potentially be a useful marker for the assessment 
and management of LUTS.(75) 
Leonardo et al. in their study on Intravesical Protrusion of the Prostate as a 
Predictive Method of Bladder Outlet Obstruction concluded that IPP and 
Prostate volume measured by transabdominal ultrasound are useful in the 
diagnosis of male urinary obstructive symptoms. 59.5% of the patients 
evaluated were found to have IPP > 10mm.(76) 
In our study 42% of men who presented with acute urinary retention had 
significant Intravesical prostatic protrusion (>10mm). 
In our study, we found that IPP and Prostate volume correlate well with one 
another. With higher prostate volume, it is also likely to have a higher grade 
IPP. Also, in our study all patients with significant IPP had a severe IPSS 
grading. Although our study demonstrates good correlation between Prostate 
Volume and Intravesical Prostatic Protrusion, the importance of measuring IPP 
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is most evident in small prostate glands with obstruction. These glands tend to 
have a significant IPP. The high IPP is due to a protruding median lobe 
creating a ball- valve effect while voiding. A strong bladder contraction force 
could open a channel between the lobes but it aggravates the ball valve effect in 
IPP, increasing the urethral resistance.(77) In addition, presence of median lobe 
enlargement causes dyskinetic movement during micturition.(65, 77) 
IPP measurement can easily be obtained from a transabdominal USG in an 
outpatient setting and is a non-invasive, reproducible and a cost-effective 
procedure.  
All patients in our study with significant IPP had a severe IPSS grade. Previous 
studies (Cumpanas et al. and Mariappan et al.) have shown that trial voiding 
without catheter is likely to fail in these patients. Hence greater emphasis is 
warranted in the evaluation of BPH during decision making in offering 
treatment options. 
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CONCLUSION 
 
Our study concludes that Intravesical Prostatic Prutrusion and Prostate 
Volume correlates well with one another and that there is high prevalence of 
significant IPP in patients eventually developing Acute Urinary Retention. All 
patients in our study with significant IPP had a severe IPSS grade. IPP can be 
used to direct appropriate patients to more aggressive treatment strategies like 
surgery. 
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ABBREVIATIONS 
 
BPH- Benign Prostatic Hyperplasia 
AUR- Acute Urinary Retention 
PV- Prostate Volume 
IPP- Intravesical Prostatic Protrusion 
IPSS - International Prostate Symptom Score  
DRE- Digital Rectal Examination 
LUTS- Lower Urinary Tract Symptoms 
BOO- Bladder Outlet Obstruction 
PSA- Prostate Specific Antigen 
USG- Ultrasonogram 
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CONSENT FORM 
 
PART 1 OF 2 
 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
Dear Volunteers, 
 We welcome you and thank you for your keen interest in participation in 
this research project. Before you participate in this study, it is important for you 
to understand why this research is being carried out. This form will provide you 
all the relevant details of this research. It will explain the nature, the purpose, 
the benefits, the risks, the discomforts, the precautions and the information 
about how this project will be carried out. It is important that you read and 
understand the contents of the form carefully. This form may contain certain 
scientific terms and hence, if you have any doubts or if you want more 
information, you are free to ask the study personnel or the contact person 
mentioned below before you give consent and also at any time during the entire 
course of the project. 
1. Name of the Principal Investigator: Dr. JishnuPalliyani 
                                                                             Post Graduate  
Department of General Surgery 
SreeMookambika Institute of Medical 
Sciences,Kulasekharam 
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2. Name of  the Guide  :          Dr. J. Jayakumar Sahayam 
Professor 
Department of General Surgery 
SreeMookambika Institute of medical 
sciences, Kulasekharam 
 
3. Institute   :  
SreeMookambika Institute of Medical Sciences, Kulasekharam 
Kanyakumari district – 629161, Tamil Nadu 
4. Title of the study: 
A Study on Intravesical Prostatic Protrusion and Prostate Volume in patients 
presenting with Acute Urinary Retention 
5. Background information 
Benign prostatic hyperplasia (BPH) is one of the most common diseases in 
elderly men. The prevalence of histological BPH increases with age and 
appears in approximately 40% of men aged 50-60 years and in approximately 
90% of men aged more than 80 years. Acute urinary retention (AUR) 
represents one of most significant and painful events in the natural history of 
benign prostatic hyperplasia (BPH). Up to a third of patients undergoing 
surgical treatment for BPH present with acute urinary retention (AUR).  
Intravesical Prostatic Protrusion (IPP) is a morphological change due to 
overgrowth of prostatic median and lateral lobes into the bladder and may lead 
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to diskinetic movement of bladder during voiding. Several studies have 
previously demonstrated that the ultrasonographic measurement of IPP is able 
to detect Bladder Outlet Obstruction (BOO) in BPH patients quickly and non-
invasively.  
This is a Study on Intravesical Prostatic Protrusion and Prostate volume in 
patients presenting with Acute Urinary Retention due to BPH 
.6. Aims and Objectives:  
 To find out the prevalence of significant Intravesical Prostatic Protrusion  (IPP)  
in patients presenting with acute urinary retention (AUR) due to Benign 
Prostatic Hyperplasia (BPH) 
 To study the correlation between IPP and Prostatic Volume 
7. Scientific Justification of the study:  
Ten per cent of men in their seventies and 30% in their eighties will have AUR 
within the next five years.  Benign prostatic hyperplasia is the cause for the 
AUR in at least 65% of men presenting with AUR. Men with AUR often have 
lower urinary tract symptoms (LUTS) for an average of 32 months prior to the 
AUR.(2).Up to a third of patients undergoing surgical treatment for BPH present 
with acute urinary retention (AUR). Acute urinary retention is associated with 
significant anxiety, discomfort and patient inconvenience. The impact on 
patients' health-related quality of life is comparable to an attack of renal 
colic(2). 
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But the symptoms and obstruction do not entirely depend on prostate’s size. In 
contrast, intravesical prostatic protrusion (IPP) has been found to correlate with 
Bladder Outlet Obstruction(1). In patients with LUTS, detection of significant 
IPP can be an indication for early surgical intervention. 
Hence in this study, we are doing a hospital based study to find out the 
prevalence of Intravesical Prostatic Protrusion and the correlation between 
Intravesical Prostatic Protrusion and Prostate Volume in patients presenting 
with Acute Urinary Retention due to BPH. 
8. Procedure of Study: 
After acceptation of the thesis by the ethics committee, an informed consent 
will be obtained from those patients presenting with Acute Urinary Retention, 
to General Surgery OPD of Sree Mookambika Institute of Medical Sciences, 
who fulfill the criteria of inclusion. Relevant clinical data (demographic-age, 
sex, place, occupation) including history will be obtained from the patient. 
History taking: 
Proforma is used for documenting age/sex/address/clinical 
information/symptoms/predisposing factors and any previous history of 
treatment. 
Measurements 
Intravesical Protrusion of Prostate and Prostatic Volume will be assessed by 
Trans-abdominal Ultrasonogram and will be carried out in the Department of 
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Radiodiagnosis, Sree Mookambika Institute of Medical Sciences, 
Kulasekharam. 
 
 IPP < 10mm is considered  not significant. 
 IPP > 10mm is considered significant 
 Normal Prostate Volume : 15 – 20 cc 
9.Expected risks for the patients: Minimal risk 
10. Expected benefits of research for the participants: 
To measure Intravesical protrusion of prostate and prostate volume in BPH 
patients examined. Detection of significant Intravesical protrusion of prostate 
in participants can be an indication for early surgical intervention. 
11. Maintenance of Confidentiality :All data collected for the study will 
be kept confidentially and would reflect on general statistical evaluation only, 
would not reveal any personal details. 
12 Why have I been chosen to be in the study? 
 You have been found to be diagnosed with Acute Urinary Retention and 
fulfil the criteria of selection 
 You are ready to give consent 
13. How many people will be there in the study: 68 
14 Agreement of compensation to the participant: In case of study related  
injury, the participant will be provided standard medical care and treatment as 
per the institutional guidelines. 
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15 Anticipated prorated payment, if any, to the participant(s) of the study: 
Nil 
 
16 Can I withdraw from the study at any time during the study period: Yes  
 
17 If there is any new findings/information, would I be informed: Yes 
 
18 Expected duration of Participant’s participation in the study: Single visit 
 
19 Whom do I contact for further information: Dr. Jishnu Palliyani 
 
 
 
Place: Kulasekharam 
Date: 
 
Signature of Principal Investigator 
 
 
Place: Kulasekharam     Signature of the 
Principal 
 Investigator 
Date: 
                                                         Signature of the Participant 
 
 
 
 
For any study related queries, you are free to contact 
Dr. Jishnu Palliyani 
MS General Surgery Post Graduate 
Department of General Surgery 
Sere Mookambika Institute of Medical Science, Kulasekharam 
Mobile No: 9585946723 
Email ID: pjishnu@hotmail.com 
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CONSENT FORM 
PART 2 0F 2 
PARTICIPANTS CONSENT FORM 
The principal investigator has explained to me in writing the details of the 
study “A Study on Intravesical Prostatic Protrusion and Prostate Volume in 
SreeMookambika Institute of Medical Sciences, Kulasekharam” to be 
conducted in the department of General Surgery, SreeMookambika Institute of 
Medical Sciences, Kulasekharam. He has also explained to me that by being a 
part of this study no new medication will be tried out on me. I confirm that I 
have understood the study and had the opportunity to ask questions. I am aware 
of my right to opt out of this study at any stage without any hindrance to my 
ongoing treatment. No additional financial burden will be placed on me by 
being part of this study. Data collected for the study will be kept under strict 
confidentiality and would reflect on general statistical evaluation only and 
would not reveal any personal details. Keeping the above facts in mind I, whole 
heartedly, without any compulsion agree to participate in this study. 
 
Signature of the investigator         Signature of 
the patient  
 
Signature of the witness 
 
Address of the patient 
 
Date: 
Place: 
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SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES 
Department of General Surgery 
Kulasekharam,Kanyakumari District,Tamil Nadu,India 
 
 
 
 
Name:      Age:    Gender: 
 
Occupation:     Education: 
 
MR number:     Study number: 
 
 
Address with contact number: 
 
 
 
 
Date of examination: 
 
Chief complaints: 
 
 
 
History of presenting illness: 
 
CASE RECORD 
FORM 
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Other diseases (if any): 
 
 
General Physical Examination: 
 
 
 
Systemic Examination: 
 
 CVS : 
 
 RS : 
 
CNS : 
 
PA : 
 
DRE Findings: 
 
 
USG Findings: 
 
 
 
 
Impression: 
 
 
 
 
- 97 - 
 
\Sl. 
No 
 
Symptom 
(In the Past 
Month) 
 
Not at 
all 
 
<1 time 
in 5 
 
Less than 
half the 
time 
 
 
About 
half the 
time 
 
More 
than 
half the 
time 
 
Almost 
always 
1 Incomplete 
Emptying 
 
How often have 
you had the 
sensation of not 
emptying 
your bladder? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
2 Frequency 
 
How often have 
you had to 
urinate less than 
every two hours? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
3  
Intermittency 
How often have 
you found 
you stopped and 
started again 
several times 
when you 
urinated? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
4  
Urgency 
How often have 
you found it 
difficult to 
postpone 
urination? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
5  
Weak Stream 
How often have 
you had a weak 
urinary stream? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
6  
Straining 
How often have 
you had to strain 
to start urination? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 None 1 time 2 times 3 times 4 times 5 times 
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7  
Nocturia 
How many times 
did you typically 
get up at night to 
urinate? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
Total IPSS  
 
      
 
 
Quality of life due to urinary symptoms [Table 2] 
 
Quality of Life 
Due to 
Urinary 
Symptoms 
 
Deligh
ted 
 
Pleased 
Mostly 
satisfied 
Mixed- 
about 
equally 
satisfied and 
dissatisfied 
Mostly 
dissatisf
ied 
Unhappy Terribl
e 
 
If you were to 
spend the rest 
of your life 
with your 
urinary 
condition just 
the way it is 
now, how 
would you feel 
about that? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
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KEY TO MASTERCHART 
 
Prostate Volume: measured in cubic centimetre  
IPP: Intravesical Prostatic Protrusion measured in millimetres 
Prostate Grade:  
  1- Grade I 
 2- Grade II 
 3- Grade III 
 4- Grade IV 
Significant IPP: Presence of IPP > 10mm 
 1- YES 
 2- NO 
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IPSS: International Prostate Symptom Score 
Sl. 
No 
Symptom 
(In the Past 
Month) 
Not at all <1 time 
in 5 
Less than 
half the 
time 
About half 
the time 
More than 
half the 
time 
Almost 
always 
1 Incomplete 
Emptying 
 
0 
 
1 
2 3  
4 
 
5 
2 Frequency 0 1 2 3 4 5 
3 Intermittency 0 1 2 3 4 5 
4 Urgency 0 1 2 3 4 5 
5 Weak Stream 0 1 2 3 4 5 
6 Straining 0 1 2 3 4 5 
 None 1 time 2 times 3 times 4 times 5 times 
7 Nocturia 0 1 2 3 4 5 
 
IPSS Grade :  IPSS 8-19- Moderate 
    IPSS 20-35- Severe 
Quality of life:   
0 Delighted 
1 Pleased 
2 Mostly satisfied 
3 Mixed- about equally satisfied and dissatisfied 
4 Mostly dissatisfied 
5 Unhappy 
6 Terrible 
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Previous AUR 
 1- Patient has a h/o previous Acute Urinary Retention 
 0- Patient has no history of previous AUR 
Pus cells in Urine Routine Examination: 
 1- Yes 
 0- No 
Prostate Tenderness 
 1- Yes 
 0- No 
MASTER CHART
SL 
No. IP No. Name Age
Prostate volume 
in cu mm IPP in mm
Prostate 
Grade Significant IPP 
Quality of 
Life IPSS
IPSS 
Grade
Previous 
AUR
Pus cells in 
urine routine 
Examination
Prostate 
Tenderness
I
n
c
o
m
p
l
e
t
e
 
E
m
p
t
y
i
n
g
F
r
e
q
u
e
n
c
y
I
n
t
e
m
i
t
t
e
n
c
y
U
r
g
e
n
c
y
W
e
a
k
 
S
t
r
e
a
m
S
t
r
a
i
n
i
n
g
N
o
c
t
u
r
i
a
1 1603109 Antony 64 74 14 3 1 4 4 3 3 4 4 4 5 26 Severe 1 0 0
2 1606141 Moosa 60 75 13 3 1 4 5 3 5 5 4 4 5 30 Severe 0 1 0
3 1607813 Sivarayan 65 84 15 3 1 4 4 4 4 5 5 5 5 31 Severe 0 1 0
4 1618794 Mani 64 70 9 3 0 3 4 2 3 4 3 3 5 22 Severe 0 1 1
5 1600694 Abdul Jabber 60 59 5 2 0 2 3 2 3 3 4 3 4 20 Severe 1 1 0
6 1606644 Alphonse 55 48 5 2 0 1 3 3 2 3 4 3 5 19 Moderate 0 1 0
7 1612750 Lekshmanan 70 78 14 3 1 3 5 4 3 4 5 4 4 28 Severe 1 1 1
8 2244990 Thomas 60 26 7 1 0 2 3 2 2 3 3 3 5 18 Moderate 0 1 0
9 2245632 Shakul Hameed 67 33 7 1 0 2 3 4 2 4 4 3 5 22 Severe 0 1 0
10 1610250 gopi 74 76 12 3 1 4 5 4 4 4 5 4 4 30 Severe 0 0 0
11 1610465 Vijayakumaran Nair 79 75 13 3 1 3 5 5 3 5 5 4 5 30 Severe 0 0 0
12 1611856 Baskaran Nair 80 104 23 4 1 5 4 5 5 4 4 5 4 32 Severe 1 0 0
13 1609226 Manikandan 45 28 5 1 0 1 4 4 2 3 3 3 5 20 Severe 0 0 0
14 1612642 Sunder Raj 62 48 4 2 0 2 3 3 4 3 3 3 5 21 Severe 0 0 0
15 1618843 Stephen 50 57 5 2 0 3 2 3 3 3 4 3 5 21 Severe 0 1 0
16 1624397 sugumaran 56 58 4 2 0 2 3 2 3 3 4 3 4 20 Severe 0 0 0
17 2242214 Narayanan Nair 76 89 15 3 1 5 4 3 3 5 5 4 4 29 Severe 1 1 0
18 1716483 Narayanan Thampi 83 89 20 3 1 4 4 4 5 5 4 4 5 30 Severe 0 0 0
19 1608846 mallik Muhammed 65 57 8 2 0 3 5 2 5 4 4 3 4 26 Severe 0 1 0
20 1609295 Thankappan 64 69 7 3 0 3 3 4 4 3 4 3 5 24 Severe 1 0 0
21 1719483 Chellan 73 95 18 4 1 5 5 3 4 4 5 5 5 31 Severe 1 1 0
22 1720328 Vijayan 57 97 22 4 1 5 4 2 4 5 4 3 4 27 Severe 1 1 0
23 1602956 Ramnathan 85 104 19 4 1 4 5 2 3 5 5 4 5 28 Severe 1 1 1
24 1710745 Krishnan Nair 74 50 5 2 0 2 3 3 3 3 3 3 5 20 Severe 0 0 0
25 1711145 Sudalai Pandi 59 51 5 2 0 1 2 2 3 3 3 3 4 17 Moderate 0 0 0
26 1711814 Ganandhas 64 53 4 2 0 2 3 2 2 3 3 3 4 18 Moderate 0 0 0
27 1711484 Barghavan 65 48 5 2 0 2 4 2 2 3 3 3 5 19 Moderate 0 0 0
28 1713691 santhosam 68 83 15 3 1 3 3 4 4 5 4 4 5 27 Severe 0 1 0
29 1715546 Murugesan Asari 60 87 13 3 1 4 4 2 5 5 4 4 5 28 Severe 0 0 0
30 1602548 velayuthan 80 88 9 3 0 3 5 3 5 5 3 3 5 27 Severe 1 1 0
31 1608573 Dennisan 62 77 9 3 0 3 4 4 3 4 3 3 4 24 Severe 0 1 0
32 1616885 ramayyan 71 47 6 2 0 2 5 2 4 5 4 4 5 26 Severe 0 0 0
33 1606892 Nagarajan 62 51 7 2 0 2 4 2 4 4 3 4 5 23 Severe 0 1 0
34 1718118 Krishnan Nair 73 91 17 4 1 5 5 4 5 5 5 4 5 33 Severe 0 0 0
35 1719073 Theiva Paul Suther 60 99 15 4 1 5 4 3 5 5 5 4 5 31 Severe 0 1 0
36 1609213 Prabhakaran 63 39 9 1 0 2 2 3 4 4 3 4 5 22 Severe 1 1 1
37 1627888 Thomas 67 48 8 2 0 2 3 3 2 4 3 4 5 21 Severe 0 0 0
38 1627635 Tharananthiran 68 44 6 2 0 3 4 4 2 3 4 3 4 23 Severe 0 0 0
39 1628086 Yovas 70 51 7 2 0 3 3 2 3 3 4 3 5 21 Severe 0 1 0
40 1628522 Pachiammal 70 62 8 3 0 2 4 3 4 3 3 3 5 22 Severe 0 1 0
IPSS Components
MASTER CHART
SL 
No. IP No. Name Age
Prostate volume 
in cu mm IPP in mm
Prostate 
Grade Significant IPP 
Quality of 
Life IPSS
IPSS 
Grade
Previous 
AUR
Pus cells in 
urine routine 
Examination
Prostate 
Tenderness
(Y/N)
I
n
c
o
m
p
l
e
t
e
 
E
m
p
t
y
i
n
g
F
r
e
q
u
e
n
c
y
I
n
t
e
m
i
t
t
e
n
c
y
U
r
g
e
n
c
y
W
e
a
k
 
S
t
r
e
a
m
S
t
r
a
i
n
i
n
g
N
o
c
t
u
r
i
a
Y/N Y/N
41 1615898 samsuden 80 100 18 4 1 5 4 4 4 4 4 4 5 29 Severe 0 1 0
42 1618014 Nesamani 70 84 11 3 1 4 5 3 4 5 4 5 5 30 Severe 0 0 0
43 242558 Kamaleshan 55 23 4 1 0 2 4 3 4 3 3 3 5 22 Severe 0 0 1
44 167789 Boominathan 67 56 5 2 0 2 4 2 3 3 3 3 5 20 Severe 0 0 0
45 2465231 Devadhas 54 58 5 2 0 2 3 2 3 3 3 3 5 19 Moderate 0 0 0
46 1626997 Abdul Asis 50 67 14 3 1 4 4 4 4 4 4 4 5 28 Severe 0 1 0
47 1629127 Sundar Raj 63 70 12 3 1 4 5 3 4 5 5 4 5 30 Severe 0 1 0
48 1629126 Thanka Raj 65 71 15 3 1 5 4 4 5 5 4 5 5 32 Severe 0 0 0
49 2242468 Nadarajan 60 90 15 3 1 4 5 4 4 4 4 5 4 30 Severe 1 1 1
50 1701676 Shivanandan 70 57 5 2 0 2 3 2 2 4 3 3 5 19 Moderate 0 0 0
51 1703321 Kumaraswami 67 58 5 2 0 1 4 3 2 3 3 3 5 19 Moderate 1 1 1
52 1620608 Muppudathi 82 105 15 4 1 5 5 4 4 5 5 4 4 32 Severe 1 0 0
53 1622210 Marimuthu 75 96 15 4 1 5 4 4 5 4 4 5 4 31 Severe 0 1 0
54 1627871 Vijaya Raj 70 96 16 4 1 4 4 3 3 4 4 3 5 25 Severe 0 0 0
55 1705517 John 60 42 4 2 0 1 3 3 2 4 3 3 4 19 Moderate 0 1 0
56 1706096 Krishnan 65 41 5 2 0 2 4 3 2 3 3 3 5 20 Severe 1 0 0
57 1709417 Chellaiyan 67 37 4 1 0 2 3 3 3 3 3 3 4 20 Severe 0 1 0
58 2245178 Krishnan Kutty 70 88 18 3 1 3 5 2 4 5 3 4 4 26 Severe 0 0 0
59 2245189 Ragavan 54 72 13 3 1 4 5 4 4 4 4 3 5 28 Severe 1 1 0
60 2245652 Sudhakaran 65 77 12 3 1 3 4 3 4 4 3 4 4 25 Severe 0 1 0
61 1712928 Arumugam 65 81 16 3 1 3 4 3 4 5 3 4 5 26 Severe 0 0 0
62 1619829 Pushpakaran 72 27 4 1 0 1 4 3 2 3 3 3 5 19 Moderate 0 0 0
63 1620700 Narayana Perumal 66 28 4 1 0 2 4 3 2 3 3 3 4 20 Severe 0 1 0
64 1622904 Sukumaran 65 27 4 1 0 2 3 3 2 3 3 3 4 19 Moderate 0 1 0
65 1623232 Damodharan 68 35 4 1 0 2 3 2 3 3 3 3 4 19 Moderate 0 0 0
66 1611551 Chinkarayan 52 38 4 1 0 1 4 2 3 3 3 3 4 19 Moderate 0 0 0
67 1613729 Savari Muthu 74 34 4 1 0 2 4 3 3 3 3 3 4 21 Severe 0 1 0
68 1613300 george 63 39 4 1 0 2 3 3 3 3 3 3 4 20 Severe 0 0 0
IPSS Components
